Literature DB >> 19190105

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.

Haixia Guan1, Meiju Ji, Rong Bao, Hongyu Yu, Yangang Wang, Peng Hou, Yong Zhang, Zhongyan Shan, Weiping Teng, Mingzhao Xing.   

Abstract

CONTEXT: Epidemiological studies have indicated that high iodine intake might be a risk factor for papillary thyroid cancer (PTC), which commonly harbors the oncogenic T1799A BRAF mutation.
OBJECTIVE: The objective of the study was to investigate the relationship between BRAF mutation in PTC and iodine intake in patients. SUBJECTS AND METHODS: We analyzed and compared the prevalences of the T1799A BRAF mutation in classical PTC of 1032 patients from five regions in China that uniquely harbor different iodine contents in natural drinking water, ranging from normal (10-21 microg/liter) to high (104-287 microg/liter). The BRAF mutation was identified by direct DNA sequencing.
RESULTS: The prevalence of BRAF mutation was significantly higher in any of the regions with high iodine content than any of the regions with normal iodine content. Overall, BRAF mutation was found in 387 of 559 PTC with high iodine content (69%) vs. 252 of 473 PTC with normal iodine content (53%), with an odds ratio of 1.97 (95% confidence interval 1.53-2.55) for the association of BRAF mutation with high iodine content (P < 0.0001). In addition, clinicopathological correlation analysis, the largest one of its type ever, showed that BRAF mutation was significantly associated with extrathyroidal invasion, lymph node metastasis, and advanced tumor stages of PTC.
CONCLUSIONS: High iodine intake seems to be a significant risk factor for the occurrence of BRAF mutation in thyroid gland and may therefore be a risk factor for the development of PTC. This large study also confirmed the association of BRAF mutation with poorer clinicopathological outcomes of PTC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19190105     DOI: 10.1210/jc.2008-2390

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  85 in total

1.  Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation.

Authors:  Thomas J Musholt; Sonja Schönefeld; Christina H Schwarz; Felix M Watzka; Petra B Musholt; Christian Fottner; Matthias M Weber; Erik Springer; Arno Schad
Journal:  Langenbecks Arch Surg       Date:  2010-07-18       Impact factor: 3.445

Review 2.  Synchronous occurrence of medullary and papillary carcinoma of the thyroid in a patient with cutaneous melanoma: determination of BRAFV600E in peripheral blood and tissues. Report of a case and review of the literature.

Authors:  Benedetta Fibbi; Pamela Pinzani; Francesca Salvianti; Matteo Rossi; Luisa Petrone; Maria Laura De Feo; Roberto Panconesi; Vania Vezzosi; Simonetta Bianchi; Gabriele Simontacchi; Monica Mangoni; Maurizio Pertici; Gianni Forti; Cinzia Pupilli
Journal:  Endocr Pathol       Date:  2014-09       Impact factor: 3.943

3.  Adolescent and mid-life diet and subsequent risk of thyroid cancer in the NIH-AARP diet and health study.

Authors:  Melissa Z Braganza; Nancy Potischman; Yikyung Park; Frances E Thompson; Albert R Hollenbeck; Cari M Kitahara
Journal:  Int J Cancer       Date:  2015-06-22       Impact factor: 7.396

4.  Health disparities in endocrine disorders: biological, clinical, and nonclinical factors--an Endocrine Society scientific statement.

Authors:  Sherita Hill Golden; Arleen Brown; Jane A Cauley; Marshall H Chin; Tiffany L Gary-Webb; Catherine Kim; Julie Ann Sosa; Anne E Sumner; Blair Anton
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

5.  The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma.

Authors:  Yun Zhang; Jiaqi Dai; Tingting Wu; Nailin Yang; Zhiqiang Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-12       Impact factor: 4.553

6.  Molecular profiles of papillary thyroid tumors have been changing in the last decades: how could we explain it?

Authors:  Rossella Elisei
Journal:  J Clin Endocrinol Metab       Date:  2014-02       Impact factor: 5.958

7.  BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients.

Authors:  F J Huang; W Y Fang; L Ye; X F Zhang; L Y Shen; R L Han; Q Wei; X C Fei; X Chen; W Q Wang; S Wang; G Ning
Journal:  Curr Oncol       Date:  2014-12       Impact factor: 3.677

8.  Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?

Authors:  Kathleen C Lee; Carol Li; Eric B Schneider; Yongchun Wang; Helina Somervell; Matthew Krafft; Christopher B Umbricht; Martha A Zeiger
Journal:  Surgery       Date:  2012-10-11       Impact factor: 3.982

9.  Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.

Authors:  Bálint Tobiás; Csaba Halászlaki; Bernadett Balla; János P Kósa; Kristóf Árvai; Péter Horváth; István Takács; Zsolt Nagy; Evelin Horváth; János Horányi; Balázs Járay; Eszter Székely; Tamás Székely; Gabriella Győri; Zsuzsanna Putz; Magdolna Dank; Zsuzsanna Valkusz; Béla Vasas; Béla Iványi; Péter Lakatos
Journal:  Pathol Oncol Res       Date:  2015-08-11       Impact factor: 3.201

10.  Strong association of relatively low and extremely excessive iodine intakes with thyroid cancer in an iodine-replete area.

Authors:  Hye Jeong Kim; Na Kyung Kim; Hyeong Kyu Park; Dong Won Byun; Kyoil Suh; Myung Hi Yoo; Yong-Ki Min; Sun Wook Kim; Jae Hoon Chung
Journal:  Eur J Nutr       Date:  2016-01-08       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.